Go Pro
→ Bezos… DOOMED (From Paradigm Press) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Absci Corporation stock logo
ABSI
Absci
$8.72
-7.4%		$9.29
$2.24
▼
$12.06
$1.50B2.354.40 million shs1.79 million shs
I-Mab Sponsored ADR stock logo
IMAB
I-Mab
$4.76
+2.5%		$4.76
$0.81
▼
$6.79
$388.29M1.451.61 million shs1.51 million shs
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
$124.17
+0.2%		$93.69
$26.19
▼
$155.29
$1.83B3.51313,509 shs139,575 shs
TRAX
First Tracks Biotherapeutics
$42.83
-4.3%		$35.23
$14.72
▼
$49.91
$1.53BN/A627,449 shs227,484 shs
7 Stocks to Buy Before the Robotics Revolution Cover
7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Absci Corporation stock logo
ABSI
Absci
+2.17%+1.51%+32.12%+39.56%+269.41%
I-Mab Sponsored ADR stock logo
IMAB
I-Mab
0.00%0.00%0.00%0.00%+5.67%
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
-1.12%+24.99%+55.53%+19.22%+352.30%
TRAX
First Tracks Biotherapeutics
+1.24%+6.78%+6.91%+180.33%+4,473,999,900.00%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Absci Corporation stock logo
ABSI
Absci
$8.72
-7.4%		$9.29
$2.24
▼
$12.06
$1.50B2.354.40 million shs1.79 million shs
I-Mab Sponsored ADR stock logo
IMAB
I-Mab
$4.76
+2.5%		$4.76
$0.81
▼
$6.79
$388.29M1.451.61 million shs1.51 million shs
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
$124.17
+0.2%		$93.69
$26.19
▼
$155.29
$1.83B3.51313,509 shs139,575 shs
TRAX
First Tracks Biotherapeutics
$42.83
-4.3%		$35.23
$14.72
▼
$49.91
$1.53BN/A627,449 shs227,484 shs
7 Stocks to Buy Before the Robotics Revolution Cover
7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Absci Corporation stock logo
ABSI
Absci
+2.17%+1.51%+32.12%+39.56%+269.41%
I-Mab Sponsored ADR stock logo
IMAB
I-Mab
0.00%0.00%0.00%0.00%+5.67%
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
-1.12%+24.99%+55.53%+19.22%+352.30%
TRAX
First Tracks Biotherapeutics
+1.24%+6.78%+6.91%+180.33%+4,473,999,900.00%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Absci Corporation stock logo
ABSI
Absci
2.78
Moderate Buy$13.4354.00% Upside
I-Mab Sponsored ADR stock logo
IMAB
I-Mab
2.83
Moderate Buy$7.6059.83% Upside
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
2.50
Moderate Buy$197.5058.77% Upside
TRAX
First Tracks Biotherapeutics
2.73
Moderate Buy$63.0046.31% Upside

Current Analyst Ratings Breakdown

Latest IMAB, TRAX, INBX, and ABSI Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/27/2026
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
Citigroup Inc. logo
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingMarket Perform
8/24/2026
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$245.00
8/18/2026
TRAX
First Tracks Biotherapeutics
Wolfe Research logo
Wolfe Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOutperform$83.00
8/13/2026
TRAX
First Tracks Biotherapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageSell (D)
8/13/2026
TRAX
First Tracks Biotherapeutics
Piper Sandler logo
Piper Sandler
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$54.00 ➝ $95.00
8/13/2026
TRAX
First Tracks Biotherapeutics
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$44.00 ➝ $57.00
8/13/2026
TRAX
First Tracks Biotherapeutics
Barclays PLC logo
Barclays
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$48.00 ➝ $65.00
8/13/2026
TRAX
First Tracks Biotherapeutics
Wedbush logo
Wedbush
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOutperform$60.00 ➝ $70.00
8/12/2026
Absci Corporation stock logo
ABSI
Absci
BTIG Research logo
BTIG Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$13.00
8/12/2026
Absci Corporation stock logo
ABSI
Absci
Needham & Company LLC logo
Needham & Company LLC
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$11.00
8/10/2026
TRAX
First Tracks Biotherapeutics
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$45.00 ➝ $65.00
(Data available from 8/28/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Absci Corporation stock logo
ABSI
Absci
$1.56M958.66N/AN/A$1.43 per share6.10
I-Mab Sponsored ADR stock logo
IMAB
I-Mab
N/AN/AN/AN/A$2.47 per shareN/A
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
$1.30M1,408.48N/AN/A($3.60) per share-34.55
TRAX
First Tracks Biotherapeutics
N/AN/AN/AN/A$4.72 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Absci Corporation stock logo
ABSI
Absci
-$115.18M-$0.80N/AN/AN/A-7,756.38%-61.71%-54.52%11/16/2026 (Estimated)
I-Mab Sponsored ADR stock logo
IMAB
I-Mab
-$22.23M-$0.36N/AN/AN/AN/A-19.65%-18.58%N/A
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
-$140.05M-$8.88N/AN/AN/AN/A-563.90%-83.48%11/13/2026 (Estimated)
TRAX
First Tracks Biotherapeutics
N/A-$1.84N/AN/AN/AN/AN/AN/AN/A

Latest IMAB, TRAX, INBX, and ABSI Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/13/2026Q2 2026
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
-$2.28-$2.34-$0.06-$2.34N/AN/A
8/12/2026Q2 2026
TRAX
First Tracks Biotherapeutics
-$0.74-$0.95-$0.21-$0.95N/AN/A
8/11/2026Q2 2026
Absci Corporation stock logo
ABSI
Absci
-$0.1910-$0.21-$0.0190-$0.21$0.92 million$0.32 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Absci Corporation stock logo
ABSI
Absci
N/AN/AN/AN/AN/A
I-Mab Sponsored ADR stock logo
IMAB
I-Mab
N/AN/AN/AN/AN/A
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
N/AN/AN/AN/AN/A
TRAX
First Tracks Biotherapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Absci Corporation stock logo
ABSI
Absci
N/A
10.63
10.63
I-Mab Sponsored ADR stock logo
IMAB
I-Mab
N/A
22.82
22.82
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
12.58
5.07
5.07
TRAX
First Tracks Biotherapeutics
N/A
14.28
14.28

Institutional Ownership

CompanyInstitutional Ownership
Absci Corporation stock logo
ABSI
Absci
52.05%
I-Mab Sponsored ADR stock logo
IMAB
I-Mab
38.38%
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
82.46%
TRAX
First Tracks Biotherapeutics
N/A

Insider Ownership

CompanyInsider Ownership
Absci Corporation stock logo
ABSI
Absci
10.52%
I-Mab Sponsored ADR stock logo
IMAB
I-Mab
22.10%
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
18.26%
TRAX
First Tracks Biotherapeutics
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
Absci Corporation stock logo
ABSI
Absci
210171.61 million153.56 millionOptionable
I-Mab Sponsored ADR stock logo
IMAB
I-Mab
38081.66 million63.61 millionOptionable
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
16614.72 million12.03 millionOptionable
TRAX
First Tracks Biotherapeutics
N/A35.73 millionN/AN/A

Recent News About These Companies

First Tracks Biotherapeutics Announces Participation in September Investor Conferences
August 26 at 4:15 PM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/26/3351693/0/en/first-tracks-biotherapeutics-announces-participation-in-september-investor-conferences.html
Wolfe Research Initiates Coverage on First Tracks Biotherapeutics (NASDAQ:TRAX)
August 20, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30971441
Wolfe Research Begins Coverage on First Tracks Biotherapeutics (NASDAQ:TRAX)
August 18, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/wolfe-research-begins-coverage-on-first-tracks-biotherapeutics-nasdaqtrax-2026-08-18/
HC Wainwright Issues Pessimistic Outlook for TRAX Earnings
August 17, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30965085
HC Wainwright Issues Pessimistic Forecast for TRAX Earnings
August 17, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/hc-wainwright-issues-pessimistic-forecast-for-trax-earnings-2026-08-17/
Analysts Offer Insights on NA Companies: Cerebras Systems, Inc. Class A (CBRS), CitroTech (CITR) and First Tracks Biotherapeutics Inc (TRAX)
August 14, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/CBRS/pressreleases/3848972/analysts-offer-insights-on-na-companies-cerebras-systems-inc-class-a-cbrs-citrotech-citr-and-first-tracks-biotherapeutics-inc-trax/
Barclays Sticks to Its Buy Rating for First Tracks Biotherapeutics Inc (TRAX)
August 14, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/markets-news/Tipranks/3846416/barclays-sticks-to-its-buy-rating-for-first-tracks-biotherapeutics-inc-trax/
First Tracks Biotherapeutics Analysts Increase Their Forecasts After Q2 Results
August 13, 2026  |  benzinga.comhttps://www.benzinga.com/analyst-stock-ratings/price-target/26/08/61173753/first-tracks-biotherapeutics-analysts-increase-their-forecasts-after-q2-results
Wedbush Issues Positive Forecast for First Tracks Biotherapeutics (NASDAQ:TRAX) Stock Price
August 13, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/wedbush-issues-positive-forecast-for-first-tracks-biotherapeutics-nasdaqtrax-stock-price-2026-08-13/
First Tracks Biotherapeutics Announces Second Quarter 2026 Financial Results and Provides Business Update
August 12, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/12/3344098/0/en/first-tracks-biotherapeutics-announces-second-quarter-2026-financial-results-and-provides-business-update.html
First Tracks Biotherapeutics Inc (TRAX) Gets a Buy from Wells Fargo
July 29, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/markets-news/Tipranks/3518217/first-tracks-biotherapeutics-inc-trax-gets-a-buy-from-wells-fargo/
TRAX stock hits all-time high — what's driving the super rally?
July 10, 2026  |  msn.comhttps://www.msn.com/en-in/autos/general/trax-stock-hits-all-time-high-what-s-driving-the-super-rally/ar-AA27EVaA
First Tracks Biotherapeutics Inc
June 30, 2026  |  cnn.comhttps://www.cnn.com/markets/stocks/TRAX
First Tracks Biotherapeutics Shares Edge Up on Sublease Deal
June 23, 2026  |  marketwatch.comhttps://www.marketwatch.com/story/first-tracks-biotherapeutics-shares-edge-up-on-sublease-deal-d03bc231
J.P. Morgan Sticks to Its Buy Rating for First Tracks Biotherapeutics Inc (TRAX)
May 24, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/markets-news/Tipranks/2108166/j-p-morgan-sticks-to-its-buy-rating-for-first-tracks-biotherapeutics-inc-trax/
First Tracks Biotherapeutics Announces Participation in Upcoming Investor Conferences
May 21, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/21/3299739/0/en/first-tracks-biotherapeutics-announces-participation-in-upcoming-investor-conferences.html
First Tracks Biotherapeutics Inc: First Tracks Biotherapeutics Announces First Quarter 2026 Financial Results and Provides Business Update
May 16, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-05/68505682-first-tracks-biotherapeutics-inc-first-tracks-biotherapeutics-announces-first-quarter-2026-financial-results-and-provides-business-update-399.htm
First Tracks Biotherapeutics Inc.
May 14, 2026  |  wsj.comhttps://www.wsj.com/market-data/quotes/TRAX/financials
First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued : TRAXV
May 14, 2026  |  247wallst.comhttps://247wallst.com/companies/traxv/
First Tracks Biotherapeutics Announces First Quarter 2026 Financial Results and Provides Business Update
May 14, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/14/3295401/0/en/first-tracks-biotherapeutics-announces-first-quarter-2026-financial-results-and-provides-business-update.html
First Tracks Biotherapeutics Inc TRAX
May 13, 2026  |  morningstar.comM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Absci stock logo

Absci NASDAQ:ABSI

$8.74 -0.68 (-7.22%)
As of 03:15 PM Eastern

Absci Corporation operates as a data-first generative artificial intelligence (AI) drug creation company in the United States. The company combines AI with scalable wet lab technologies to create biologics for patients. Its integrated drug creation platform is designed to improve upon traditional biologic drug discovery by using AI to simultaneously optimize multiple drug characteristics that may be important to development and therapeutic benefit. The company was founded in 2011 and is headquartered in Vancouver, Washington.

I-Mab stock logo

I-Mab NASDAQ:IMAB

I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics in the fields of immuno-oncology and immuno-inflammation diseases primarily in the United States. It is developing Uliledlimab, a CD73 neutralizing antibody, which is in Phase 2 clinical trial for the treatment of solid tumors; Givastomig, a bi-specific antibody that is in Phase 1 clinical trial for the treatment of gastric and other cancers; and Ragistomig, a programmed cell death ligand-based tumor-dependent T cell engager, which is in Phase 1 clinical trial for the treatment of for solid tumors. The company is also evaluating opportunities to develop Lemzoparlimab, a fully human CD47 monoclonal antibody for cancer immunotherapy. It has strategic licensing agreement with Ferring International Center SA to research, develop, make, have made, import, use, sell and offer to sell FE301, an interleukin-6 inhibitor. The company has clinical collaboration with Bristol Myers Squibb to evaluate Claudin 18.2 x 4-1BB bispecific antibody givastomig in combination with nivolumab and chemotherapy for the treatment of gastric and esophageal cancer. I-Mab was founded in 2014 and is headquartered in Rockville, Maryland.

Inhibrx Biosciences stock logo

Inhibrx Biosciences NASDAQ:INBX

$125.66 +1.73 (+1.40%)
As of 03:15 PM Eastern

Inhibrx, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also develops INBRX-109, a tetravalent therapeutic candidate targeting death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, colorectal cancer, ewing sarcoma, and pancreatic adenocarcinoma; and INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company has license and collaboration agreements with 2seventy bio, Inc. and Bristol-Myers Squibb Company. Inhibrx, Inc. was incorporated in 2009 and is headquartered in La Jolla, California.

First Tracks Biotherapeutics NASDAQ:TRAX

$42.90 -1.84 (-4.11%)
As of 03:13 PM Eastern

First Tracks Biotherapeutics is a clinical stage biotechnology company advancing antibody therapies which modulate immune pathways implicated in autoimmune and inflammatory diseases. Its pipeline includes ANB033 and ANB101. First Tracks Biotherapeutics is based in SAN DIEGO.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas